Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

UBS analyst Dan Leonard lowered the firm’s price target on Fulgent Genetics (FLGT) to $20 from $27 and keeps a Neutral rating on the shares.

Piper Sandler analyst David Westenberg lowered the firm’s price target on Fulgent Genetics (FLGT) to $16 from $22 following quarterly results.

Fulgent Genetics (($FLGT)) has held its Q4 earnings call. Read on for the main highlights of the call. Fulgent Genetics’ recent earnings call ...

Proficio Capital Partners LLC bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Full Year 2024 Results Key Financial Results Revenue: US$283.5m (down 2.0% from ...

Discover the top 5 undervalued Health Care Providers & Services stocks for Wednesday, March 12 based on AAII’s Stock Grades.

Fulgent Genetics ( NASDAQ:FLGT ) Full Year 2024 Results Key Financial Results Revenue: US$283.5m (down 2.0% from FY... EL MONTE, Calif., February 28, 2025--Fulgent Genetics, Inc. (NASDAQ ...

StockNews.com upgraded shares of Fulgent Genetics (NASDAQ:FLGT – Free Report) from a sell rating to a hold rating in a research report released on Wednesday. Separately, Piper Sandler decreased their ...

FULGENT GENETICS ($FLGT) is expected to release its quarterly earnings data on Friday, February 28th before market open, per Finnhub. Analysts are expecting revenue ...

Greetings and welcome to the Fulgent Genetics Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode. [Operator Instructions]. A question-and-answer session ...